 |
|
|
| |
Switching to dolutegravir/lamivudine two-drug regimen:
durability and virologic outcomes in
routine U.S. clinical care
|
| |
| |
AIDS 2022 July 29- Aug 1 Montreal
Gerald Pierone1, Laurence Brunet2, Jennifer S Fusco2, Cassidy Henegar3, Supriya Sarkar3, Jean van Wyk4, Vani Vannappagari3, Gregory P Fusco2
1 Whole Family Health Center, Vero Beach, FL, USA; 2 Epividian, Durham, NC, USA; 3 ViiV Healthcare, Research Triangle Park, NC, USA; 4 ViiV Healthcare, Brentford, UK
|
| |
|
|
|
|
|
